Among these biomarkers, the majority of data are for alpha-fetoprotein (AFP), which is demonstrated to be a useful predictor of the risk of drop-out while on the waiting list for LT, the risk of tumor recurrence after LT and overall survival (OS) (Table 2). The gene discussed is AFP; the disease is neoplasm.